Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0C2IA
|
||||
| Former ID |
DIB014301
|
||||
| Drug Name |
DPC-168
|
||||
| Indication | Allergic rhinitis [ICD9: 472.0, 477, 995.3; ICD10:J00, J30, J31.0, T78.4] | Discontinued in Phase 1 | [1] | ||
| Company |
Bristol-Myers Squibb Pharma Co
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
S(=O)(=O)(c1ccccc1)O.C(=O)(N[C@H]1[C@H](CN2C[C@H](Cc3cc<br />c(F)cc3)CCC2)CCCC1)Nc1cc(C(=O)C)ccc1
|
||||
| Target and Pathway | |||||
| Target(s) | C-C chemokine receptor type 3 | Target Info | Antagonist | [2] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| Chemokine signaling pathway | |||||
| Viral carcinogenesis | |||||
| NetPath Pathway | IL3 Signaling Pathway | ||||
| PANTHER Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | ||||
| Reactome | Chemokine receptors bind chemokines | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| IL1 and megakaryotyces in obesity | |||||
| IL-3 Signaling Pathway | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015460) | ||||
| REF 2 | CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2992-7. Epub 2007 Mar 24. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.